局部进展期胃癌新辅助治疗的研究现状

Research Status of Neoadjuvant Therapy for Locally Advanced Gastric Cancer

在我国,胃癌的早期发现及诊断率比较低,多数的胃癌患者出现症状而就诊时已发展为局部进展期;伴随着胃癌治疗模式的更新与进步,局部进展期胃癌(Local advanced gastric cancer, LAGC)的治疗模式已转变为多学科治疗的综合治疗模式,LAGC的新辅助治疗更是在其综合治疗中占据重要的地位。LAGC患者接受新辅助治疗,可使原肿瘤病症、隐匿的淋巴结缩小或消失,其肿瘤分期下降的几率升高,手术及根治性手术成功率提高,减少肿瘤手术后的复发率。进行新辅助治疗的肿瘤患者的体力、相关药物的耐受性等优于辅助治疗的患者,利于治疗周期很好的完成,从而为LAGC患者带来受益。

Early detection and diagnosis of gastric cancer are relatively low in our country, and most patients with gastric cancer develop local progression when they show symptoms and attend a clinic. With the update and progression of gastric cancer treatment models, the local advanced gastric cancer (LAGC) treatment model has been transformed into a multidisciplinary approach to combination therapy, and new adjuvant therapies for LAGC occupy a significant place in its portfolio. In LAGC pa-tients undergoing neoadjuvant therapy, tumor stage decreased, tumor lesions and hidden lymph nodes shrank or disappeared, increasing surgical and radical surgical success and reducing recur-rence after tumor surgery. Patients with neoadjuvant therapy have better physical strength and re-sistance to associated drugs than patients with adjuvant therapy, enabling a good completion of the treatment cycle, thus benefiting LAGC patients.